Delving into the Latest Updates on Direct Therapeutics, Inc. with Synapse

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of carmustine in treating patients who have progressive or recurrent glioblastoma multiforme.

开始日期2000-06-01

申办/合作机构

Direct Therapeutics, Inc.

NCT00009854 / Unknown status临床1/2期

Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients who have recurrent supratentorial malignant glioma or metastatic brain neoplasm.

开始日期2000-06-01

申办/合作机构

Direct Therapeutics, Inc.

NCT00038441 / Completed临床1/2期IIT

Phase I Trial of Intratumoral Injection of DTI-015 for Recurrent Malignant Gliomas

This is a clinical research study of a new investigational treatment for cancer called "DTI-015" to be given by intratumoral injection. Intratumoral injection is when drug is injected directly into the tumor. This study will help doctors find out what is the best dose level for DTI-015 and if this treatment can shrink tumors without causing severe side effects. The effects of the drug on the patient's quality of life (how the patient feels and what the patient can do) and their mental functions (reasoning and thinking abilities) will also be studied.

开始日期1995-09-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与 Direct Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Direct Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Direct Therapeutics, Inc. 相关的文献（医药）

2004-12-01·Clinical Cancer Research1区 · 医学

Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker

1区 · 医学

Article

作者: Moffat, Bradford A. ; Johnson, Timothy D. ; Chenevert, Thomas L. ; Hamstra, Daniel A. ; Stojanovska, Jadranka ; Carter, Julie ; Rehemtulla, Alnawaz ; Li, Zhuolin ; Ross, Brian D. ; Hall, Daniel E. ; Pietronigro, Dennis

AbstractTo investigate diffusion weighted magnetic resonance imaging as a quantitative surrogate marker for evaluating the therapy-induced cellular changes in an orthotopic experimental glioma model, tumors were treated with direct intratumoral administration of DTI-015, a solution of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in 100% EtOH. Intracerebral 9L tumors were induced in Fischer 344 rats, and three treatment groups were established: DTI-015, EtOH, and sham. Two groups of rats received intratumoral injection of either 67 mg/mL BCNU in EtOH or EtOH alone at 50% of the tumor volume up to a maximum of 30 μl under stereotactic guidance. Diffusion magnetic resonance images were acquired before treatment and after treatment at 1, 24, 48, and 72 hours and then 3 times per week thereafter. Tumor cell viability was examined using multislice diffusion weighted magnetic resonance imaging with diffusion weighted transverse magnetic resonance images and histogram plots of each tumor quantified over time. Control animals (EtOH- or sham-treated animals) showed mean apparent diffusion coefficients (ADCs) that remained essentially unchanged over the experimental time course. In contrast, rats treated with DTI-015 showed a significant increase in ADC relative to the pretreatment within 24 hours, which further increased over time, followed by a significant therapeutic response as evidenced by subsequent tumor volume shrinkage, development of a cystic region, and enhanced animal survival. Finally, not only were ADC measurements predictive of differences between treatment groups, but they also yielded spatial and temporal data regarding the efficacy of treatment within individual treated animals that could be used to guide subsequent therapy.

100 项与 Direct Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Direct Therapeutics, Inc. 相关的转化医学

登录后查看更多信息